Originally published as JCO Early Release 10.1200/JCO.2005.05.0401 on November 6 2006
Journal of Clinical Oncology, Vol 24, No 34 (December 1), 2006: pp. 5343-5349
© 2006 American Society of Clinical Oncology.
Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study
Asher Chanan-Khan,
Kena C. Miller,
Laurie Musial,
David Lawrence,
Swaminathan Padmanabhan,
Kenichi Takeshita,
Carl W. Porter,
David W. Goodrich,
Zale P. Bernstein,
Paul Wallace,
David Spaner,
Alice Mohr,
Catriona Byrne,
Francisco Hernandez-Ilizaliturri,
Cynthia Chrystal,
Petr Starostik,
Myron S. Czuczman
From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
Address reprint requests to Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton St, Buffalo, NY 14263; e-mail: asher.chanan-khan{at}roswellpark.org
PURPOSE: Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have profound immune defects and limited treatment options. Given the dramatic activity of lenalidomide in other B-cell malignancies and its pleotropic immunomodulatory effects, we conducted a phase II trial of this agent in CLL.
PATIENTS AND METHODS: Patients with relapsed or refractory B-cell CLL (B-CLL) were eligible if they required treatment as per the National Cancer Institute Working Group 1996 guidelines. Lenalidomide was administered orally at 25 mg on days 1 through 21 of a 28-day cycle. Response was assessed after each cycle. Patients were to continue treatment until disease progression, unacceptable toxicity, or complete remission. Rituximab was added to lenalidomide on disease progression.
RESULTS: Forty-five patients were enrolled, with a median age of 64 years. Sixty-four percent of the patients had Rai stage III or IV disease, and 51% were refractory to fludarabine. The overall response rate was 47%, with 9% of the patients attaining a complete remission. Fatigue, thrombocytopenia, and neutropenia were the most common adverse effects noted in 83%, 78%, and 78% of the patients, respectively.
CONCLUSION: Lenalidomide is clinically active in patients with relapsed or refractory B-CLL. These findings are encouraging and warrant further investigation of this agent in the treatment of this disorder.
published online ahead of print at www.jco.org on November 6, 2006.
Supported by Celgene Corporation, Summit, NJ.
Presented in part at the XI International Workshop on Chronic Lymphocytic Leukemia, September 16–18, 2005, Brooklyn, NY; the 47th Annual Meeting of the American Society of Hematology, December 10–13, 2005, Atlanta, GA; and the 41st Annual Meeting of the American Society of Clinical Oncology, May 13–17, 2005, Orlando, FL.
Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Related Correspondence
- Tumor Lysis Syndrome/Tumor Flare Reaction in Lenalidomide-Treated Chronic Lymphocytic Leukemia
Laure A. Moutouh-de Parseval, Lilia Weiss, Robert J. DeLap, Robert D. Knight, and Jerome B. Zeldis
JCO 2007 25: 5047
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
T. S. Lin
Lenalidomide: what is the right dose in CLL?
Blood,
June 1, 2008;
111(11):
5268 - 5268.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ferrajoli, B.-N. Lee, E. J. Schlette, S. M. O'Brien, H. Gao, S. Wen, W. G. Wierda, Z. Estrov, S. Faderl, E. N. Cohen, et al.
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Blood,
June 1, 2008;
111(11):
5291 - 5297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Andritsos, A. J. Johnson, G. Lozanski, W. Blum, C. Kefauver, F. Awan, L. L. Smith, R. Lapalombella, S. E. May, C. A. Raymond, et al.
Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 20, 2008;
26(15):
2519 - 2525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Chanan-Khan and B. D. Cheson
Lenalidomide for the Treatment of B-Cell Malignancies
J. Clin. Oncol.,
March 20, 2008;
26(9):
1544 - 1552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda
Treatments for Patients with Chronic Lymphocytic Leukemia
ASCO Educational Book,
January 1, 2008;
2008(1):
297 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Blum, D. Young, S. Broering, M. S. Lucas, B. Fischer, T. S. Lin, M. R. Grever, and J. C. Byrd
Computed Tomography Scans Do Not Improve the Predictive Power of 1996 National Cancer Institute Sponsored Working Group Chronic Lymphocytic Leukemia Response Criteria
J. Clin. Oncol.,
December 10, 2007;
25(35):
5624 - 5629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Fine, L. Kim, P. S. Albert, J. P. Duic, H. Ma, W. Zhang, T. Tohnya, W. D. Figg, and C. Royce
A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors
Clin. Cancer Res.,
December 1, 2007;
13(23):
7101 - 7106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Chen, H. Lau, L. Kong, G. Kumar, J. B. Zeldis, R. Knight, and O. L. Laskin
Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis
J. Clin. Pharmacol.,
December 1, 2007;
47(12):
1466 - 1475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Moutouh-de Parseval, L. Weiss, R. J. DeLap, R. D. Knight, and J. B. Zeldis
Tumor Lysis Syndrome/Tumor Flare Reaction in Lenalidomide-Treated Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
November 1, 2007;
25(31):
5047 - 5047.
[Full Text]
[PDF]
|
|
|
|
